Advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression.
VIEW PRODUCT PIPELINEAbout
We are a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders.
Read MoreNews
Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 9, 2024
Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024
May 8, 2024
Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference
May 7, 2024
Product Pipeline
Azetukalner
for Focal Onset Seizures (FOS)
X-TOLE2/3 Clinical Trial
Azetukalner
for Primary Generalized Tonic-Clonic Seizures (PGTCS)
X-ACKT Clinical Trial
Azetukalner
for Major Depressive Disorder (MDD)
X-NOVA Clinical trial
Azetukalner
for MDD
Investigator-led Phase 2 POC study Collaboration with Mount Sinai
Kv7
Potassium Channel Openers
Nav1.7
Sodium Channel Inhibitors
Nav1.1
Sodium Channel Openers
NBI-921352
for Rare Pediatric Epilepsy: SCN8A-DEE
Partnered with Neurocrine Biosciences
Investors
Visit our Investor page for News Releases, Annual & Quarterly Reports, Webcasts & Events
View Investor Area